2 results
Approved WMOCompleted
The overall aim of the study is to evaluate the difference in speech performance of a new hands-free speech valve as compared to the currently most used (Atos) exhalation speech valve.
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.